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Background. There is inconclusive evidence from cross-sectional and cohort studies that arsenic exposure is a risk factor involved
in the development of hypertension. Methods. A database search, using several keywords, was conducted to identify relevant
studies. Separate odds ratio estimates for arsenic exposure with concentration only and arsenic exposure with duration, including
biomarker, were extracted from studies that met all inclusion criteria. The extracted odds ratios (OR) comparing the highest
exposure categories with the lowest in each study were pooled using the random eﬀects methods of meta-analysis. Heterogeneity
of odds ratios in the included studies were analyzed using I2 statistics. Results. Eight studies were analyzed. Using the exposure as
arsenicconcentrationinthedrinkingwater,theORestimatewas1.9(95%CI:1.2–3.0),withtheI2 =92%,whileusingtheexposure
as concentration and duration, the OR estimate was 1.4 (95% CI: 0.95–2.0) with the I2 = 80%. Meta-regression was done and the
quality of exposure measurement was found to be signiﬁcantly associated with the eﬀect measure. For a one unit increase in the
score from exposure assessment, the odds ratio decreased by 6%. No publication bias was evident. The only major weaknesses of
this study were heterogeneity across studies and small sample size. Conclusions. The study ﬁndings provide limited evidence for a
relationship between arsenic and hypertension. In summary, the relationship between arsenic exposure and hypertension is still
inconclusive and needs further validation through prospective cohort studies.
1.Introduction
Arsenic is a known carcinogen [1], and increasing evidence
alsosuggestsapossibleroleofchronicarsenicexposureinthe
development of chronic diseases, including cardiovascular
diseases [2]. Cardiovascular diseases associated with high
levelsofarsenicinthedrinkingwaterincludeatherosclerosis,
hypertension, cerebrovascular diseases, ischemic heart dis-
eases, and peripheral vascular disease [3, 4].
The possible role of chronic arsenic exposure in the
development of hypertension has been previously reported
from Taiwan, Bangladesh, and the United States [5–7].
These studies reported that individuals drinking arsenic-
contaminated water for a long period of time might be at
higher risk of developing hypertension compared to those
unexposed to arsenic, and the eﬀects were dose dependent.
Hypertension is one of the major risk factors for car-
diovascular diseases [8] and is considered a major public
health problem worldwide [9]. A total of 972 million adults
were reported to have hypertension in 2000 and that number
is estimated to increase by 60%, to a total of 1.56 billion,
by the year 2025 [9]. The economic costs associated with
hypertension are also very high.
To date, only a few cross-sectional and cohort studies
have investigated the association between hypertension and
chronic arsenic exposure [10]. Therefore, it is important
from the public health perspective to explore the role of
chronic arsenic exposure in development and prevention of2 Journal of Toxicology
hypertension. In this study, we conducted a meta-analysis
that included all relevant cross-sectional and cohort studies
of chronic arsenic exposure and hypertension. The meta-
analysis provides greater precision in estimating risk espe-
cially when data are scarce and inconclusive. Our analysis
includes a careful assessment of the possible eﬀects of study
quality as well as other biases on the meta-analysis results.
2.MaterialsandMethods
2.1.LiteratureSearch. Weusedacomprehensivesearchstrat-
egy to identify all relevant studies. The research question was
deﬁned as “Is there any association between chronic arsenic
exposure and hypertension?” This question was then broken
d o w nt oc o v e rs p e c i ﬁ cs e a r c ht e r m ss u c ha s“ h y p e r t e n s i o n , ”
“chronicarsenicexposure,” “arsenite,”“arsenosis,” “arsenico-
sis,”“diastolic,”and“systolic.”Eachtermwasincluded inone
or more searches. The search was ﬁrst carried out in Ovid
MEDLINE and Google Scholar in September 2009, without
limitation on the time of publication. We also replicated the
searchinEMBASEandPubMed,butnoadditionalreferences
were identiﬁed through these databases. The search was last
updated in February 2012 to locate new studies published
after the initial search. No new studies on this topic had been
published. The references cited in the collected list of articles
were also hand-searched for additional relevant studies.
2.2. Selection of Studies. The included studies (1) were obser-
vational studies, that is, cross-sectional, case control or
cohort studies, of chronic arsenic exposure through drinking
water and hypertension, (2) reported a relative risk (RR)
or odds ratio (OR), or such parameters could be estimated
from the published data, and (3) measured arsenic, using a
laboratory technique.
Two investigators (T. A. and R. E. Y.) screened the initial
list of articles to identify articles that were irrelevant and,
therefore, discarded from the list. To facilitate faster screen-
ing,articleswereﬁrstjudgedonthebasisoftheirtitles,where
obviously irrelevant articles were discarded. The abstracts of
the remaining articles were then read by three investigators
(T. A., B. R., and A. H. M.) to ensure that the main subject of
the study was related to arsenic exposure and hypertension.
Articles whose abstracts showed that the study was not
relevant to the objective of the meta-analysis were discarded.
Final screening of the articles was based on the full content.
Afterthescreening,informationforthearticleswasextracted
and a quality evaluation was done.
2.3. Data Extraction. A data extraction format was prepared
to extract relevant information from the individual studies.
The data items extracted from each study were
(i) general information: ﬁrst author’s name and aﬃl-
iation, year of publication, country, and region in
which the study was conducted;
(ii) study design: population, number and sources of
study participants, and type of study;
(iii) exposure and outcome measurement: analytical
methods for measuring arsenic, speciation of arsenic,
duration of arsenic exposure, relevant information
on individual level of exposure assessment, and mea-
surement of hypertension;
(iv) analysis: covariates for adjustment in multivariate
models, adjusted and unadjusted or stratiﬁed eﬀect
estimates (i.e., RR and OR) and 95% conﬁdence
intervals (CIs). If a study did not report CIs, the stan-
dard error and the resulting CI from the P value were
estimated [11], where possible.
For cross-sectional studies, ORs were extracted as the
estimate of the eﬀect of arsenic exposure. For cohort studies,
the RRs were used.
2.4. Quality of the Studies. Each article was evaluated in a
standardised manner to assess its individual qualities. Qual-
ity assessment was facilitated through the use of a stan-
dardised questionnaire which was developed speciﬁcally for
this study. The questionnaire was a comprehensive scor-
ing instrument based on critical appraisal principles and
understanding of the methodological issues of population
selection, measurement of arsenic exposure and outcome,
adjustment for potential confounders, and appropriateness
of analysis. Each criterion was given weighted scores to eval-
uate the quality of the studies in comparison to each other,
with key factors being given speciﬁc scores. Although the
scoring in itself can be subjective, it enables comparisons
amongthestudies.Threeindependentreaders(T.A.,R.E.Y.,
and A. F.) scored each of the studies and were blinded to the
others’ assessments. Any signiﬁcant disagreement between
the readers was resolved through discussion. For minor
diﬀerences, the average score was used as the agreed score.
This resulted in a single agreed score for each characteristic
of each paper.
The maximum score value that could be assigned to each
study was 100, and this score summarised the overall quality
of the study. The score was the weighted sum of four major
domains of quality: selection issues (score weight 20%),
measurement issues (of exposure and outcome, score weight
50%),adjustmentofconfoundingfactors(scoreweight20%)
and analysis (score weight 10%). The analysis section was
given the least weight because if the other three sections were
of good quality but the analysis was not carried out properly,
the data could often be reanalyzed. Two scoring systems
were developed, one for cross-sectional studies and one
for prospective studies. Each of the studies was subjectively
assessed and scored using these instruments.
3.StatisticalAnalysis
To assess the interrater reliability of the study quality scores,
reliability and reproducibility were analyzed by computing
intraclass correlation coeﬃcients (ICCs) for absolute agree-
ment between raters on each quality domain along with the
overall score.
To conduct the meta-analysis, ORs were extracted from
cohort studies and used to estimate the eﬀects, with the
exceptionofonecohortstudywheretheRRwasusedinstead.
For studies where several measures of association wereJournal of Toxicology 3
reported, associations which related hypertension to amount
of arsenic intake, or to arsenic intake combined with dura-
tion of exposure, were considered. Pooled ORs were esti-
mated by comparing the highest exposure category to the
lowest one combined for males and females.
Themeta-analysisincluded checkingforheterogeneityof
the ORs, checking for inﬂuential studies, checking for asym-
metry and publication biases, and checking for relationships
between the log of eﬀect measures and the article’s quality
scores.
Eﬀect estimates (ORs) were pooled using DerSimo-
nian and Laird’s inverse-variance-weighted random eﬀects
method [12]. Heterogeneity was measured using the I2-
statistic [13], which describes the proportion of total vari-
ation in study estimates that is due to heterogeneity [13].
The inﬂuence of each study on the pooled eﬀect measure was
examinedbyrepeatingthemeta-analysiswhileomittingeach
study one by one.
A Funnel plot was used to check for potential publication
bias [14]. This was also objectively measured using Begg’s
statistic [15]. A random eﬀect metaregression was conducted
using the logs of the eﬀect measures (OR) as the outcome
variable and the study quality score as the explanatory vari-
able to assess the possible impact of study quality on the
eﬀect measures. These random eﬀect models were ﬁtted with
two additive variance components: within study variance
and between study residuals [16, 17]. All meta-analysis was
conducted using STATA version 11.0 SE.
4. Results
4.1. Literature Survey. The database search yielded 85 arti-
cles,10ofwhichinvestigatedtheassociationbetweenchronic
arsenic exposure and hypertension. Two of these articles
were excluded from the meta-analysis because the full texts
were not available. Thus, the ﬁnal meta-analysis comprised
eight studies: seven analytical cross-sectional studies and one
prospectivecohortstudy.Oftheseeightstudies,tworeported
arsenic concentration only as exposure, two reported
arsenic concentration and duration of drinking arsenic-
contaminated water as a combined exposure value, and three
reported arsenic concentration and arsenic concentration
and duration of exposure separately. Table 1 provides a
summary of the relevant studies.
4.2. Quality Scoring. T h ea v e r a g et o t a ls c o r e sa n da v e r a g e
per criterion scores for quality assessment are summarized
in Table 2. The scores are percentages out of the highest
possible score per criterion. The one cohort study scored
better in the domains of Selection and Outcome compared
to the other seven cross-sectional studies. The cohort study
had a Selection score of 18.7 (of 20 possible), while the
cross-sectional studies averaged 15.8. The cohort had an
Outcome score of 16 (of 20 possible), while the 7 cross-
sectional studies averaged 14.7. In particular, the study by
Zierold et al. [18] scored low in this domain (1.3) due to
missing details in the report. The 7 cross-sectional studies
scored higher in the Exposure (cross-sectional = 24.3, cohort
= 20, of 30 possible) and Confounders(cross-sectional = 18.6,
cohort = 10, of 20 possible) domains. The Analysis (cohort =
9.3, cross-sectional = 10, of 10 possible) domain scores were
similar; but, overall, the cross-sectional studies (total score =
84.1) scored higher than the cohort study (total score = 74).
Goodinterobserveragreementonthetotalqualityscoreswas
veriﬁed by the intraclass correlation coeﬃcient (ICC). The
total score ICC was 0.88 (95% CI: 0.62–0.98). The highest
agreement was seen among scores for the Exposure (ICC =
0.87 95% CI: .56–.98) and Outcome (ICC = 0.96 95% CI:
0.64–1.00) domains, and the lowest for the Analysis (ICC =
0.001 95% CI: −0.24–0.78) domain. The low ICC, however,
was due to one rater’s disagreement on one study, but there
was perfect agreement among the raters on the rest of the
studies. Other domains showed moderate agreement: the
ICC for Confounders was 0.59 (95% CI: −0.19–0.90) while
that for Selection was 0.66 (95% CI: −0.01–0.93).
The eight selected studies were scored based on criteria
that were speciﬁcally developed to assess their quality. The
cohort study by Wang et al. [5] scored a total of 74 points,
having scored well on Selection and Exposure but not on
Confounder criteria. The seven cross-sectional studies had an
average score of 84.1 (range = 61 to 93.3). Overall, the cross-
sectional studies scored higher than the prospective cohort
study for the Confounders and Exposure criteria but scored
lower for the Selection and Outcome criteria. The summary
of scores is presented in Table 2.
4.3. Adjustment of Potential Confounders. The studies dif-
fered in the adjustment of potential confounders, such as
age, sex, and body mass index, as well. Such diﬀerences may
add to the heterogeneity of the conclusions presented in the
articles.
5.RiskEstimateandMeta-Analysis
The pooled OR of studies using arsenic concentration as
the exposure measure was 1.9 (95% CI: 1.2–3.0), while the
pooled estimate for OR of studies using arsenic concentra-
tion and duration including biomarker as the exposure was
1.4(95%CI:0.95–2.0).Forthearsenicconcentrationstudies,
the I2 was 92% (P<0.001), while, for the concentration and
duration studies, I2 was 80% (P<0.001). A P value <0.001
suggests a strong heterogeneity across studies. The meta-
analysis results are presented with forest plots in Figure 1.
In the forest plots, the point estimate for one study is
represented by the centre of each rectangle. The size of the
rectangle is relative to the weight of the point estimate when
the results are pooled. The length of the horizontal line
through the rectangle represents the 95% conﬁdence interval
of the point estimate. The pooled estimate is represented by
the diamond on the lower portion of the plot. The vertical
axis through the diamond represents the point estimate, and
the horizontal end corners are the upper and lower 95%
conﬁdence boundaries.
5.1. Inﬂuence Analysis. The results of the inﬂuence analysis
showed that no single study exerted a disproportionate inﬂu-
ence on the pooled estimate for either arsenic concentration
or arsenic concentration and duration (Figure 2).4 Journal of Toxicology
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Table 2: Average quality scores on quality scores for studies included in the meta-analysis.
Categories of quality scoring
(maximum points value)
Average (%) of the maximum category quality score (range) ICCa for interobserver agreement
(95% CI) Cross-sectional
(n = 7)
Cohort studies
(n = 1)
Selection (20 points) 15.8 (14.7–16.0) 18.7 0.659 (−0.015–0.922)
Exposure (30 points) 24.3 (18.3–30.0) 20.0 0.870 (0.563–0.972)
Outcome (20 points) 14.7 (1.3–17.3) 16.0 0.958 (0.644–0.992)
Confounders (20 points) 18.6 (13.3–20.0) 10.0 0.578 (−0.188–0.902)
Analysis (10 points) 10 (10.0-10.0) 9.3 0.001 (−0.238–0.782)
Total quality score (100 points) 84.1 (61.0–93.3) 74.0 0.884 (0.620–0.975)
aICC: intraclass correlation coeﬃcient.
Cross-sectional: Arsenic exposure
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Figure 1: Forest plot of meta-analysis of arsenic and hypertension
in cohort and cross-sectional studies.
5.2. Publication Bias. Investigation of the publication bias
showed some evidence of positive results for the concentra-
tion and duration studies. The Egger’s test P value for arsenic
concentration studies was 1.00, while the Egger’s test P value
for the concentration and duration studies was 0.004. The
funnel plot shows possible bias only for concentration and
duration studies (Figure 3).
5.3. Metaregression. Using the scores from the Quality
assessment, a metaregression was performed to verify the
dependencyoftheOutcomemeasureonthequalityscores.Of
all the scoring criteria, the Quality of exposure measurement
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Figure 2: (a) Inﬂuence analysis for arsenic concentration as expo-
sureassessment,(b)inﬂuenceanalysisforarsenicconcentrationand
duration as exposure assessment.
and total quality was signiﬁcantly associated with the
Outcome measure. For one unit increase in the score from
the Exposure domain, the OR decreased by 6% (P = 0.004,
95% CI: 2.1%–10.7%).
6. Discussion
Inthestudiesincludedinthemeta-analysis,arsenicexposure
was measured by diﬀerent studies in diﬀerent ways. Even
when two studies used the same units of measurement,12 Journal of Toxicology
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Figure 3:(a)Plotforarsenicconcentrationasexposureassessment,
(b) funnel plot for arsenic concentration and duration as exposure
assessment.
they may still have diﬀered in categorization and deﬁnition
of subjects being exposed to arsenic. The common units
used were mg/L-year and µg/L. However, the deﬁnition of
“exposure”d i ﬀers from one study to another, since there is
no agreement on how to express the duration of exposure
or what quantities of arsenic constitute an exposure. This
problem results from the fact that external validation of the
methods used to determine exposure in studies is still prob-
lematic.Inaddition,whilemethodsfordetectionofexposure
to high levels of arsenic have been well characterized, mea-
surement of arsenic exposure at low concentrations is still
notveryreliable.Furthermore,Wangetal.[5]andChenetal.
[19] have followed the WHO protocol for the measurement
ofbloodpressureandhaveusedthecriteriaofdiastolicblood
pressure >95mmHg or systolic blood pressure >160mmHg
todeﬁnehypertension,whileHuangetal.[20],Rahmanetal.
[21], and Chen et al. [6] speciﬁed hypertension as diastolic >
90mmHg or systolic >140mmHg. In the study by Jones et
al.[22],theyfolloweddiastolicbloodpressure>90mmHgor
systolic blood pressure >140mmHg to deﬁne hypertension.
Overall, this meta-analysis suggests that chronic arsenic
exposure is likely to be associated with hypertension. The
pooled OR of arsenic concentration studies is 1.9 (95% CI:
1.2–3.0) and that for arsenic concentration and duration
studies is 1.4 (95% CI: .95–2.0). The P values for homogene-
ity for arsenic exposure were signiﬁcant at P<0.05. The I2
was 90% for arsenic concentration studies and 82.81% for
arsenic concentration and duration studies. Investigation of
publication bias showed some evidence of positive results for
concentration and duration studies. The Egger’s test P value
forarsenicconcentrationstudieswas0.828,whiletheP value
for concentration and duration studies was 0.04.
Chen et al. [10] obtained similar results in their 2007
review of arsenic, diabetes, and hypertension. This paper
included only four studies regarding arsenic exposure and
hypertension and did not include a meta-analysis. In our
meta-analysis, seven good quality studies were included
that related arsenic exposure to hypertension using proper
statistical analysis, with control groups (Table 1). As opposed
to the report of Chen et al. [6], which only presented
the results of their reviewed papers, the meta-analysis
conducted here attempted to pool the reported ORs, tested
for heterogeneity, and conducted a meta-regression. These
arethemajorstrengthsofthecurrentstudy.Tothebestofour
knowledge, this is the ﬁrst meta-analysis that has explored
the association between hypertension and chronic arsenic
exposure. One of the major limitations of this meta-analysis
is the limited number of studies examining the association
between hypertension and chronic arsenic exposure. These
studies were also heterogeneous as reﬂected by the high
values of the I2 statistics. Thus, a random eﬀects model was
used in conducting the meta-analysis.
The adverse eﬀects of arsenic on blood vessels have
been demonstrated in previous studies which reported that
constant exposure of rats and rabbits to arsenite caused a
considerable increase in peripheral vascular resistance.
The eight studies evaluated in this paper have shown
howvariedtheimpactofarseniconhypertension,depending
on factors such as sex, age, body-mass index, diabetes,
and triglyceride levels of the subject population. However,
an increased risk for hypertension among arsenic exposed
participantshasnotbeenconsistentlyobserved.Forinstance,
Dastgiri et al. [23] reported a signiﬁcant diﬀerence both for
systolic and diastolic blood pressures between exposed and
unexposedsubjects,whileKhanetal.[24]reportednosignif-
icant eﬀect. Inconsistent ﬁndings may be due to diﬀerences
in measurement criteria both for exposure and outcome
variables, or due to bias caused by limited consideration
of potential confounders. Due to these inconsistencies, the
increased prevalence of hypertension for a population that is
exposed to high arsenic levels cannot yet be established.
7. Conclusions andRecommendations
This meta-analysis suggests a possible association between
chronic arsenic exposure and hypertension. However, the
small number of studies and limitations in study quality
pose challenges to establishing causation between arsenic
exposure and hypertension. Nevertheless, since a larger
proportionoftheruralBangladeshipopulationdrinkarsenic
contaminated water and the risk of hypertension is increas-
ing among the general population, even a small association
may lead to a large number of cases and a large populationJournal of Toxicology 13
attributable risk. Therefore, the association deserves further
investigation, preferably with cohort studies.
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